Market Research Blog

Point of care cholesterol monitoring device is being used increasingly for detecting the blood analytes for further diagnosis and management. It is a modern healthcare device that enables the clinicians or patients to perform diagnostic tests outside laboratories. Its compact design and portability makes it ideal for use in obtaining results of lipoprotein and cholesterol levels in the blood. Point of care cholesterol monitoring device helps detect the total cholesterol profile. Moreover, the demand for hand held and portable devices is increasing rapidly, further boosting the demand for point of care cholesterol monitoring device.

Prevalence of Home Care to Stimulate Point of Care Cholesterol Monitoring Device Sale

Self-testing process is gaining tremendous demand lately, with its benefits that allow faster diagnosis along with a convenience factor. The rapid and seamless process of monitoring cholesterol level provided by device, ensures better health management. Moreover self-testing and home care devices act as a cost-effective way of diagnostics, making them a futuristic diagnosis device for cholesterol monitoring. For example, at-home cholesterol monitoring kits are gaining traction over the years, with the simplicity and ease associated with them.

Regulatory Approvals to Remain a Significant Milestone

With various medical device manufacturers developing point of care medical devices, there has been a rise in awareness of stringent regulations associated with the use of the point of care cholesterol monitoring device. The approval of the US FDA (Food and Drug Administration) plays a major role in the growth of the point of care cholesterol monitoring device landscape. Prominent players are on a constant focus of gaining FDA approvals for their point of care products, to ensure reliability. For example, Solana Health, a key player in the point of care cholesterol monitoring device offers a home cholesterol kit that is certified by FDA.

Tapping Opportunities in International Market with New Development

Companies are often witnessed expanding their footprint across various markets to profit from the several promising markets. For instance, ACON Laboratories, Inc., a global manufacturer of medical diagnostic products for point of care and clinical laboratory sectors, and a leading point of care cholesterol monitoring device market player recently announced that its Mission Lipid Data Management Software is made available for international customers, to use it with the Mission Cholesterol Meter, which would allow easy transfer of lipid panel results from the meter to PC. This would create and manage the electronic records securely.

The point of care cholesterol monitoring device market research report presented by Future Market Insights is a compilation of the significant growth areas of the market. The key market segment analysis, evaluation of opportunities in the major regions, and the potential scope of the market shines light on the future market scenario. Furthermore, the key developments carried out by prominent market players and the significant strategies implemented by point of care cholesterol monitoring device market players plays a crucial role in effective decision making for emerging point of care cholesterol monitoring device providers.

To avail the key insights and findings pertaining to the point of care cholesterol monitoring device, click here.

Dependency for Regulating Routine Lab Workflows Stimulating Sales of Lab Workflow Solutions

With greater dependency on sample testing in the in-vitro space in healthcare domain, it has become essential to regulate and streamline day-to-day sample processing in laboratories. With that as a primary focus of various laboratories, the essentiality of lab workflow solutions has never been so imperative than it is today. This is massively pushing the adoption of various lab workflow solutions such as software and analytics to restructure and rationalize the sample data collected in labs, which is driving the growth of lab workflow solutions market.  

In the era of IT implementation, changing reimbursement landscape and healthcare integration, improvements in lab workflow solutions should not be confined to laboratory success alone but should extend to various departments thus leveraging improvement opportunities across healthcare organizations.

Empowering Diagnostics with Lab Workflow Solutions

With increasing complexity in diagnostic laboratories, the need for critical management to ensure balance between financial and operational priorities including managing personnel, budgets, customer satisfaction and quality assurance has become vital in diagnostic laboratories. With advanced lab workflow solutions, diagnostics can be taken to a next level using a holistic approach to facilitate speed, cost reductions and quality, consequently enabling efficient implementation, laboratory benchmarking and overall lab workflow.

Lab Workflow Solutions Support in Overcoming Crucial Challenges

Laboratories typically face challenges with respect to managing high volumes of data. They need to cope up with constant and significant increase in accuracy and volume of information associated with sequencing. In addition, other challenges such as identification of scalable solutions to organize and track relevant samples and data, maintain necessary connectivity between data and samples, cutting down time needed for manual management as well as manual data processing and retrieve and store data as and when needed can be addressed using lab workflow solutions. Given these set of hurdles faced by laboratories, demand for lab workflow solutions have dramatically risen across various departments, which in turn has been instrumental in driving the growth of the lab workflow solutions market worldwide.

Cloud Transforming Lab Workflow Solutions

Pervasiveness of Internet of Things (IoT) and cloud platform has relentlessly transformed the lab workflow management space, in turn supporting adoption of lab workflow solutions. Workflow audit in labs can now be easily carried out using the cloud platform. The cloud platform can encrypt data in storage and transit enabling efficient control over routine lab workflow. The transition from archaic model of storage and collection data of samples to smart handling of data is likely to result in development of Internet of Labs along with cloud based equipment in the coming years. With cloud in the lab workflow solutions picture, it has become increasingly possible to further enhance productivity, improve traceability and reduce costs associated with maintenance.

Additionally, companies involved in lab workflow solutions are introducing advanced decision support systems to back clinical workflow and facilitate decision support. For instance, Roche has introduced “Navify” tumor board solution that expedites efficient lab workflow as well as optimize decision making apropos of cancer case reviews. It standardizes lab workflows by amassing relevant patient information and ebbs errors, facilitates effective team collaboration as well as evaluate potential treatment solutions. Likewise, Philips has launched IntelliSpace Enterprise Edition, a novel and scalable informatics system. Such developments across the entire lab workflow solutions umbrella has significantly pushed the adoption of lab workflow solutions across healthcare facilities, thus furthering the growth of the lab workflow solutions market. However, relatively high costs associated with enhanced lab workflow solutions are likely to create a major hurdle in terms of adoption and integration of such systems, particularly among small-scale laboratories.

Request Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=436

 Breast cancer drugs can also be used to treat certain targeted therapy resistant lung cancers, according to a new study. The study, conducted on mice, found that the mutations in the gene EGFR were responsible for certain lung tumors in mice. When protein p110a was blocked by drugs, the tumor shrank in size.

P110a blocking drugs are currently undergoing clinical trials against certain types of breast cancers, showing potential for use in other therapeutic areas.The findings can help EGFR mutant lung cancer patients who are undergoing treatment. Presently, the EGFR mutant lung cancer patients are treated with certain targeted therapies but unfortunately the tumors have shown a tendency to become drug resistant after initial years of therapy.

When the first line of therapy is over, it is usually followed by chemotherapy. Chemotherapy is non-targeted, and the potential side effects have created challenges. Chemotherapy has not been very effective and medical fraternity is on a lookout for a viable alternative. Researchers are now exploring the possibility whether p110a inhibitor drugs can be used for a second line of therapy in place of chemotherapy.

The team of researchers led by Dr. Julian Downward of the Francis Crick Institute and Institute of Cancer Research in United Kingdomare studying the interaction between the p110a and RAS protein. Mutation in the RAS gene is the cause of one fifth of all cancers. The unfettered growth caused by this gene is the focal point of this study.

The post intervention results of the study are quite stunning. Before the treatment, two thirds of the lung space was occupied by the tumor. When the interaction between p110a protein and RAS gene was blocked, it shrank to one tenth of the lung space.

Very few side effects were noticed in the drug trails. The trials were conducted only on mice, a rare genetic technique not possibly viable for treatment on human subjects was used. Even though Dr. Julian sees great future in blocking this pathway, he clarifies that the research is still in preliminary stages and many years away from the clinic.